Relypsa Stock Price, News & Analysis (NASDAQ:RLYP)

Previous Close$31.99
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio-5.55
Dividend YieldN/A

About Relypsa (NASDAQ:RLYP)

Relypsa logoRelypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.

Receive RLYP News and Ratings via Email

Sign-up to receive the latest news and ratings for RLYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-5.55208333333333
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($5.76)
Net IncomeN/A
Net Margins-1,601.53%
Return on Equity-227.26%
Return on Assets-115.06%


Outstanding SharesN/A

Relypsa (NASDAQ:RLYP) Frequently Asked Questions

What is Relypsa's stock symbol?

Relypsa trades on the NASDAQ under the ticker symbol "RLYP."

How were Relypsa's earnings last quarter?

Relypsa Inc (NASDAQ:RLYP) announced its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($1.26) EPS for the quarter, beating analysts' consensus estimates of ($1.46) by $0.20. The biotechnology company earned $12.40 million during the quarter, compared to the consensus estimate of $6.88 million. Relypsa had a negative return on equity of 227.26% and a negative net margin of 1,601.53%. During the same quarter in the prior year, the firm earned ($0.78) EPS. View Relypsa's Earnings History.

Who are some of Relypsa's key competitors?

Has Relypsa been receiving favorable news coverage?

News articles about RLYP stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Relypsa earned a media sentiment score of 0.08 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.15 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Relypsa?

Shares of RLYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Relypsa?

Relypsa's mailing address is 100 Cardinal Way, REDWOOD CITY, CA 94063-4755, United States. The biotechnology company can be reached via phone at +1-650-4219500.

MarketBeat Community Rating for Relypsa (RLYP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Relypsa and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Relypsa (NASDAQ:RLYP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Relypsa (NASDAQ:RLYP) Consensus Price Target History

Price Target History for Relypsa (NASDAQ:RLYP)

Relypsa (NASDAQ:RLYP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
9/1/2016WedbushDowngradeOutperform -> Neutral$32.00N/AView Rating Details
8/22/2016Stifel NicolausDowngradeBuy -> Hold$32.00N/AView Rating Details
8/13/2016MizuhoReiterated RatingNeutral$32.00N/AView Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingHold$32.00N/AView Rating Details
7/22/2016HC WainwrightDowngradeBuy -> Neutral$32.00N/AView Rating Details
7/21/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$9.00 -> $32.00N/AView Rating Details
7/21/2016CitigroupDowngradeBuy -> Neutral$25.00 -> $32.00N/AView Rating Details
7/21/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
5/31/2016OppenheimerReiterated RatingOutperform$36.00N/AView Rating Details
5/29/2016CowenReiterated RatingBuyN/AView Rating Details
4/1/2016Raymond James FinancialInitiated CoverageMarket PerformN/AView Rating Details
(Data available from 3/20/2016 forward)


Relypsa (NASDAQ:RLYP) Earnings History and Estimates Chart

Earnings by Quarter for Relypsa (NASDAQ:RLYP)

Relypsa (NASDAQ RLYP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2 2016($1.53)($1.87)$4.47 million$5.22 millionViewN/AView Earnings Details
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Relypsa (NASDAQ:RLYP) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Relypsa (NASDAQ:RLYP)

No dividend announcements for this company have been tracked by

Insider Trades

Relypsa (NASDAQ RLYP) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Relypsa (NASDAQ:RLYP)
Institutional Ownership by Quarter for Relypsa (NASDAQ:RLYP)

Relypsa (NASDAQ RLYP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2016James D DonderoMajor ShareholderBuy500$31.92$15,960.00View SEC Filing  
8/16/2016Monte MontgomeryInsiderSell510$31.92$16,279.20View SEC Filing  
8/11/2016James D DonderoMajor ShareholderSell37,000$31.96$1,182,520.00View SEC Filing  
7/25/2016Orbimed Advisors LlcMajor ShareholderSell4,043,600$32.00$129,395,200.00View SEC Filing  
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.422,729View SEC Filing  
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.0028,290View SEC Filing  
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.0033,962View SEC Filing  
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.0014,853View SEC Filing  
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  
12/9/2015Lance BermanSVPSell750$29.50$22,125.0021,290View SEC Filing  
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.0054,375View SEC Filing  
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.0021,290View SEC Filing  
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.0059,375View SEC Filing  
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  
8/17/2015Lance BermanSVPSell710$24.77$17,586.7015,040View SEC Filing  
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.5010,478View SEC Filing  
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  
(Data available from 1/1/2013 forward)


Relypsa (NASDAQ RLYP) News Headlines


SEC Filings

Relypsa (NASDAQ:RLYP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Relypsa (NASDAQ:RLYP) Income Statement, Balance Sheet and Cash Flow Statement


Relypsa (NASDAQ RLYP) Stock Chart for Tuesday, March, 20, 2018

Loading chart…

This page was last updated on 3/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.